Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on aTyr Pharma (ATYR – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $3.99.

SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Thursday reported a loss of $15 million in its fourth quarter. The San Diego-based company said it had a loss of 18 cents per share.

NASDAQ ATYR opened at $3.10 on Tuesday. Atyr PHARMA has a 52-week low of $1.42 and a 52-week high of $4.66. The company has a 50-day simple moving average of $3.66 and a 200 day simple moving ...

Cash Runway: Expected to fund operations through one year following the phase 3 FSOfi readout. aTyr Pharma Inc (NASDAQ:ATYR) completed enrollment in their global pivotal phase three Esofi study ...